Neoadjuvant HER2+ Articles

Neratinib/T-DM1 Combo Shows Promise in HER2-Positive Breast Cancer
The combination of neratinib and T-DM1 induced an overall response rate of 60% in previously-treated women with HER2-positive metastatic breast cancer. 
Tracing Tucatinib's Role in HER2+ Breast Cancer Treatment
Rashmi K. Murthy, MD, discusses the clinical benefit of tucatinib after isolated brain progression in patients with HER2-positive breast cancer.
Trastuzumab Deruxtecan Efficacious in Breast Cancer Across Varying HER2 Levels
Long-term findings from a phase I study of trastuzumab deruxtecan showed that the investigational HER2-targeting antibody-drug conjugate had antitumor activity in multiple tumor types that expressed HER2 at varying levels. 
Tucatinib Active in Heavily Pretreated HER2+ Breast Cancer
Tucatinib used in combination with capecitabine, trastuzumab, or both agents showed promising antitumor activity in heavily pretreated women with HER2-positive breast cancer with or without brain metastases. 
Trastuzumab Biosimilar Demonstrates Equivalence to Reference Product in HER2-Positive Breast Cancer
The pathologic complete response rate associated with the trastuzumab biosimilar ABP 980 was equivalent to that of reference trastuzumab based on central laboratory evaluation in patients with HER2-positive early breast cancer enrolled in the phase III LILAC study.
48 Week PFS Similar for MYL-1401O, Trastuzumab in HER2-Positive Metastatic Breast Cancer
MYL-1401O (Ogivri; trastuzumab-dkst) added to a taxane as initial therapy followed by MYL-1401O monotherapy as maintenance resulted in a nearly identical rate of progression-free survival compared with trastuzumab (Herceptin) in patients with HER2-positive metastatic breast cancer.
Endocrine Therapy Alone Is Sufficient in HR+/HER2- Breast Cancer With Intermediate Recurrence Score
Adjuvant endocrine therapy alone is noninferior to adjuvant chemoendocrine therapy in patients with hormone receptor–positive, HER2-negative, node-negative early-stage breast cancer.
Expert Recaps Adjuvant Advancements in HER2+ Breast Cancer
Haythem Y. Ali, MD, discusses adjuvant advances in HER2-postitive breast cancer and emerging agents in the field. 
Shorter Trastuzumab Duration Matches 12-Month Standard for Early HER2+ Breast Cancer
A shorter 6-month course of adjuvant trastuzumab (Herceptin) was found to be noninferior for disease-free survival compared with the standard 12-month schedule for patients with HER2-positive early breast cancer.
HER2+ Breast Cancer Outlook Improved, But More Work Remains
Kelly McCann, MD, PhD, discusses the therapies available for patients with HER2-positive breast cancer and the potential benefit with additional subtyping in the field.
Publication Bottom Border
Border Publication